Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Multiplexing Microarrays

By Drug Discovery Trends Editor | March 4, 2010

Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, has introduced three new CytoSure ISCA aCGH arrays to meet all resolution, multiplexing and budget requirements. Designed in collaboration with the International Standard Cytogenomic Array (ISCA) Consortium, the 8 x 60k, 4 x 180k and 4 x 44k CytoSure ISCA formats, provide powerful arrays focusing on disease and syndrome-associated genome regions, in addition to offering whole genome coverage. Using a proprietary 60-mer probe design and multiple rounds of optimisation, the CytoSure ISCA aCGH arrays ensure exceptional reliability and confident detection of genetic aberrations with high signal-to-noise ratios. These features have ensured that the CytoSure ISCA arrays are already used at a number of key facilities, including the Wessex Regional Genetics Laboratory, Salisbury UK where they were evaluated as part of an ongoing multi-platform aCGH comparison being carried out by the National Genetics Reference Laboratory (Wessex).

Each CytoSure array is accompanied with the user-centric CytoSure Interpret analysis software. This powerful and easy-to-use tool ensures effortless translation of data into meaningful results. Intuitive features include the “Accelerate” workflow, for customisable automation of routine data analysis, and full integration with existing data and publicly available cytogenetics databases including the Database of Genomic Variants (DGV, Canada) and DECIPHER (Sanger Institute, UK). “OGT has a strong and ongoing commitment to providing cytogeneticists with exceptional tools for accurate and reliable aberration detection” stated James Clough, OGT’s Vice President Clinical and Genomic Solutions, “The development of our CytoSure ISCA arrays, in combination with our advanced CytoSure Interpret analysis software, is a clear example of this. We are delighted by the level of interest our CytoSure ISCA arrays are generating within the ISCA consortium around the world”.

In addition to CytoSure ISCA arrays and Interpret software, the CytoSure aCGH product line includes a range of high quality arrays covering single disorders through to entire syndrome spreads, as well as SciGene automation instrumentation (now distributed in Europe by OGT). As a result, OGT’s comprehensive products and services are the ideal solution for running oligo aCGH in the laboratory.

Date: February 2, 2010
Source: Oxford Gene Technology


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE